Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-cash Items (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Non-cash Items for 7 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 93.91% to $5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Dec 2025, down 93.91% year-over-year, with the annual reading at $5.9 million for FY2025, 93.91% down from the prior year.
  • Non-cash Items for Q4 2025 was $5.9 million at Kymera Therapeutics, down from $73.5 million in the prior quarter.
  • The five-year high for Non-cash Items was $246.9 million in Q4 2021, with the low at $1.6 million in Q1 2021.
  • Average Non-cash Items over 5 years is $62.3 million, with a median of $56.5 million recorded in 2022.
  • The sharpest move saw Non-cash Items surged 8374.47% in 2022, then crashed 97.18% in 2023.
  • Over 5 years, Non-cash Items stood at $246.9 million in 2021, then plummeted by 77.35% to $55.9 million in 2022, then dropped by 11.28% to $49.6 million in 2023, then soared by 96.92% to $97.7 million in 2024, then plummeted by 93.91% to $5.9 million in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $5.9 million, $73.5 million, and $84.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.